BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to EJ-28 cell line is 34
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting and FACs | NA | 0.6 | 1 | 32661469 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.6 | 1 | 28870814 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.6 | 1 | 31180522 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | EJ-28 | Benzidine | SFA followed by Western Blotting | NA | 0.6 | 1 | 33552265 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.6 | 1 | 33552265 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.684 | 28870814 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.684 | 32661469 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.684 | 31180522 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | EJ-28 | Benzidine | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 33552265 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 33552265 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28870814 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 32661469 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | EJ-28 | Benzidine | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 33552265 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 33552265 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 28870814 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 32661469 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.6448 | 31180522 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | EJ-28 | Benzidine | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 33552265 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 33552265 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 28870814 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 32661469 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.7582 | 31180522 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | EJ-28 | Benzidine | SFA followed by Western Blotting | NA | 0.48 | 0.7582 | 33552265 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.7582 | 33552265 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.7582 | 32065779 |
| GLI1 | 4317 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0308 | 33552265 |
| GLI2 | 4318 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0106 | 33552265 |
| SHH | 10848 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 33552265 |
| SMO | 11119 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 33552265 |
| BHMT | 1047 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 32065779 |
| COX7B2 | 24381 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 32065779 |
| MAGEB2 | 6809 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 32065779 |
| SLCO1B3 | 10961 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 32065779 |
| XAGE5 | 30930 | LTM | Bladder Cancer | Carcinoma | EJ-28 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 32065779 |